|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Racl in human breast cancer: Ovcrexpression, mutation analysis, and characterization of a new isoform, Racl b 显示文摘 | Sehnelzer A Prechtel D Knaus U Dehne K Gerhard M Graeff H | 2000 | Oncogene2000，19，26： | 1 |
| 2 | Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer显示文摘 | SCHMALFELDT B PRECHTEL D HARTING K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 3 | Infection of mature dendritic cells with herpes simplex virus type 1 dramatically reduces lymphoid chemokine-mediatedmigration显示文摘 | Prechtel A T Turza N M Kobelt D J | 2005 | J Gen Virol2005，86，6： | 1 |
| 4 | Increased expression of matrix metalloproteinases (MMP) - 2, MMP - 9, and the urokinase - type plasminogen activator is associated with progression from be- nign to advanced ovarian cancer 显示文摘 | Schmalfeldt B Prechtel D Hatrting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 5 | c-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu 显示文摘 | Lengyel E Prechtel D Resau JH | 2005 | Int J Cancer2005，113，4： | 1 |
| 6 | Increased expression of matrix metalloproteinases (MMP)-2,MMP -9,and the urokinase -type plasminogen activator is associated with progression from benign to advanced ovarian cancer 显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 7 | Increased expression of matrix metalloproteinases-2,-9 and the urokinse-type plasminogen activator is associated with progression from benign to advanced ovarian cancer显示文摘 | Schrnalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 8 | Increased expression of matrix metalloproteinase( MMP-2 ), MMp-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer 显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 9 | Increased expres- sion of matrix metalloproteinases (MMP) -2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer 显示文摘 | Sehmalfeldt B Prechtel D Harting K | 2001 | Clirt Cancer2001，7，8： | 1 |
| 10 | Rac l in human breast cancer:overexpression,mutation analysis,and characterization of a new isoform,Rac lb显示文摘 | Schnelzer A Prechtel D Knaus U | 2000 | Oncogene2000，19，26： | 1 |
| 11 | Increased expression of matrix metalloproteinases (MMP)-2,MMP-9,and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 12 | C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu显示文摘 | Lengyel E Prechtel D Resau JH | 2005 | Int J Cancer2005，113，4： | 1 |
| 13 | Increased expression of matrix metalloproteinases (MMP) -2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer 显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 14 | Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 15 | Increased expression of matrix metalloproteinases (MMP)-2,MMP-9,and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer显示文摘 | Schmalfeldt B Prechtel D Hharting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 16 | C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu显示文摘 | LENGYEL E PRECHTEL D RESAU J H | 2005 | Int J Cancer2005，113，4： | 1 |
| 17 | Increased expression of matrix metalloproteinases (MMP) -2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer 显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 18 | Racl in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Raclb显示文摘 | Schnelzer A Prechtel D Knaus U | 2000 | Oncogene2000，19，26： | 1 |
| 19 | Semantic similarity analysis of user-generated content for theme-based route planning显示文摘 | Pippig K Burghardt D Prechtel N | 2013 | Journal of Location Based Services2013，7，4： | 1 |
| 20 | C-Met overexpression in node positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu 显示文摘 | Lengyel E Prechtel D Resau JH | 2005 | Int J Cancer2005，113，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员